BioSpace News Archive

Bausch Health, Canada Inc. today announced the first public drug plan listings for Pr UCERIS (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults.

Clairvoyant Therapeutics Inc. , today announced that it is on target to potentially become the first in the world to commercialize clinically validated psilocybin treatment.

Medcura, Inc. today announced that it has closed a private placement with aggregate gross proceeds of US $22.4 million (the “Offering”) in Convertible Debt.

Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3 trial evaluating the efficacy and safety of investigational raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer.

Geneoscopy, Inc. will present research at the Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference in Cambridge, Mass., April 9-10.

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.

Milestone Scientific Inc. today announced that it has commenced sales of CompuFlo ® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida.

Matinas BioPharma Holdings, Inc. announced it has entered into securities purchase agreements with healthcare-focused institutional investors for the purchase and sale of 33,333,334 shares of common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 33,333,334 shares of common stock, at a combined offering price of $0.30 per share and accompanying warrant, pursuant to a registered direct offering.

BioCorRx Inc. today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the United States Patent and Trademark Office (USPTO).

Gastrointestinal examinations can be invasive or non-invasive. Stool tests can be associated with limitations such as the amount of pathogens present being too low for culture or detection, resulting in negative PCR results.